Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor detection, technology services, equipment/reagents, laboratory overall solution, and big data services. It also offers scientific research services and medical testing services and products. In addition, the company provides GENOSi, an intelligent agent cloud platform; and NovaSeq, a next-generation sequencing platform. It serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macau, and Taiwan. The company was founded in 1997 and is headquartered in Beijing, China.
Research context
Berry Genomics Co.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Berry Genomics Co.,Ltd is currently in a long term downtrend where the price is trading 25.3% below its 200 day moving average.
From a valuation standpoint, the stock is 20.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.7.
Berry Genomics Co.,Ltd's total revenue sank by 12.8% to $367M since the same quarter in the previous year.
Its net income has dropped by 47.7% to $33M since the same quarter in the previous year.
Finally, its free cash flow grew by 116.2% to $28M since the same quarter in the previous year.
Based on the above factors, Berry Genomics Co.,Ltd gets an overall score of 2/5.